Aging-associated prostate smooth muscle hypercontractility in rats
DOI:
https://doi.org/10.1590/s2175-97902022e21063Palavras-chave:
Benign prostatic hyperplasia, Lower urinary tract symptoms, Phenylephrine, Electrical-field stimulation, Smooth muscleResumo
Benign prostatic hyperplasia (BPH) is a multifactorial disease, highly associated with aging and characterized by increased prostate smooth muscle (PSM) contractility. Animal models have been employed to explore the aging-associated PSM hypercontractility; however, studies have focused in old animals, neglecting the initial alterations in early ages. The determination of prostatic dysfunctions onset is crucial to understand the BPH pathophysiology and to propose new BPH treatments. Considering that PSM contractility in 10-month-old rats has already been explored, the aim of the present study was to characterize the PSM contractility in younger rats. Male Wistar control (3.5-month-old), 6- and 8-month-old rats were used. Concentration-response curves to phenylephrine and electrical-field stimulation (EFS) were conducted in prostate from all groups. For the first time, we showed that 6- and 8-month-old rats exhibit PSM hypercontractility. The increased prostate contractility to phenylephrine starts around at 6-month-old, worsening during the aging. The 8-month-old rats exhibited hypercontractility to phenylephrine and EFS compared to the control and 6-month-old groups. Reduced phenylephrine potency was observed in 8-month-old rats, indicating an increased age-dependent prostate sensibility to this agonist. Collectively, our findings support the use of 6- and 8-month-old aged rats as new models to explore prostate hypercontractility in BPH.
Downloads
Referências
Banerjee PP, Banerjee S, Brown TR, Zirkin BR. Androgen action in prostate function and disease. Am J Clin Exp Urol. 2018;6(2):62-77.
Calmasini FB, de Oliveira MG, Alexandre EC, Silva FH, Tavares EBG, Andre DM, et al.Obesity-induced mouse benign prostatic hyperplasia (BPH) is improved by treatment with resveratrol: implication of oxidative stress, insulin sensitivity and neuronal growth factor. J Nutr Biochem. 2018;55:53-58.
Calmasini FB, Leiria LO, Alves Junior MJ, Bau FR, Alexandre EC, Silva FH, et al. Increased Rho-kinase-mediated prostate contractions associated with impairment of beta-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency. Eur J Pharmacol. 2015;758:24-30.
Calmasini FB, McCarthy CG, Wenceslau CF, Priviero FBM, Antunes E, Webb RC. Toll-like receptor 9 regulates metabolic profile and contributes to obesity-induced benign prostatic hyperplasia in mice. Pharmacol Rep. 2020;72(1):179-187.
Calmasini FB, Silva FH, Alexandre EC, Rodrigues RL, Barbosa AP, Ferrucci DL, et al. Implication of Rho-kinase and soluble guanylyl cyclase enzymes in prostate smooth muscle dysfunction in middle-aged rats. Neurourol Urodyn. 2016;36(3):589-596.
Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12-19.
Fattahi A, Ghiasi M, Mohammadi P, Hosseinzadeh L, Adibkia K, Mohammadi G. Preparation and physicochemical characterization of prazosin conjugated PLGA nanoparticles for drug delivery of flutamide. Braz J Pharm Sci. 2018;54(4):1-10.
Golomb E, Kruglikova A, Dvir D, Parnes N, Abramovici A. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate. 1998;34(3):214-221.
Gupta NK, Gange SN, McVary KT. New and emerging technologies in treatment of lower urinary tract symptoms from benign prostatic hyperplasia. Sex Med Rev. 2019;7(3):491-498.
Lamas CA, Kido LA, Hermes TA, Nogueira-Lima E, Minatel E, Collares-Buzato CB, et al. Brazilian berry extract (Myrciaria jaboticaba): A promosing therapy to minimize prostatic inflammation and oxidative stress. Prostate. 2020;80(11):859-871.
Lau WA, Ventura S, Pennefather JN. Pharmacology of neurotransmission to the smooth muscle of the rat and the guinea-pig prostate glands. J Auton Pharmacol. 1998;18(6):349-356.
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2020 (in press).
Lee SN, Chakrabarty BW, Brad P, Melissa R, Andrew F, Mark L, et al. Age related differences in responsiveness to sildenafil and tamsulosin are due to myogenic smooth muscle tone in the human prostate. Sci Rep. 2017;7(1):10150.
Liu TT, Thomas S, McLean DT, Roldan-Alzate A, Hernando D, Ricke EA, et al. Prostate enlargement and altered urinary function are part of the aging process. Aging (Albany NY). 2019;11(9):2653-2669.
Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology. 2019;65(5):458-464.
Mazur DJ, Helfand BT, McVary KT. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. Urol Clin North Am. 2012;39(1):77-88.
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147( Suppl 2):S88-119.
Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol . 2000;20(4):193-206.
Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248-257.
Schauer IG,Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation. 2011;82(4-5):200-10.
Sievert KD, Hennenlotter J, Dillenburg T, Toomey P, Wollner J, Zweers P, et al. Extended periprostatic nerve distributions on the prostate surface confirmed using diffusion tensor imaging. BJU Int . 2019;123(6):995-1004.
Thiyagarajan M, Kaul CL, Ramarao P. Enhancement of alpha-adrenoceptor-mediated responses in prostate of testosterone-treated rat. Eur J Pharmacol. 2002;453(2-3):335-344.
Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate. 2010;70(1):79-89.
Wah W, Ahern S, Evans S, Millar J, Evans M, Earnest A. Geospatial and temporal variation of prostate cancer incidence. Public Health. 2021;190:7-15.
White CW, Short JL, Evans RJ, Ventura S. Development of a P2X1-purinoceptor mediated contractile response in the aged mouse prostate gland through slowing down ATP breakdown. Neurourol Urodyn . 2015;34(3):292-298.
Xiong Y, Zhang Y, Li X, Qin F, Yuan J. The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males. Aging Male . 2020;23(5):1432-1439.
Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
Como Citar
Dados de financiamento
-
Fundação de Amparo à Pesquisa do Estado de São Paulo
Números do Financiamento 2014/02195-6;2019/09912-9
